[go: up one dir, main page]

TN2013000494A1 - Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm - Google Patents

Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm

Info

Publication number
TN2013000494A1
TN2013000494A1 TNP2013000494A TN2013000494A TN2013000494A1 TN 2013000494 A1 TN2013000494 A1 TN 2013000494A1 TN P2013000494 A TNP2013000494 A TN P2013000494A TN 2013000494 A TN2013000494 A TN 2013000494A TN 2013000494 A1 TN2013000494 A1 TN 2013000494A1
Authority
TN
Tunisia
Prior art keywords
combination
treatment
relates
ruxolitinib
panobinostat
Prior art date
Application number
TNP2013000494A
Other languages
French (fr)
Inventor
Fabienne Baffert
Thomas Radimerski
Brian Gadbaw
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/042174 external-priority patent/WO2012174061A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2013000494A1 publication Critical patent/TN2013000494A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a combination which comprises: (a) Compound A ((R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile) of Formula (A): [Chemical formula should be inserted here as it appears in Abstract in paper form] or a pharmaceutically acceptable salt thereof; and (b) Compound B (N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide) of Formula (B): [Chemical formula should be inserted here as it appears in Abstract in paper form] or a pharmaceutically acceptable salt thereof; for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of proliferative diseases. The invention also relates to pharmaceutical compositions comprising such a combination and to a method of treating proliferative diseases, in a mammal, particularly a human, with such a combination. The present invention further also relates to a commercial package or product comprising such a combination.
TNP2013000494A 2011-12-09 2013-11-25 Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm TN2013000494A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161568717P 2011-12-09 2011-12-09
PCT/US2012/042174 WO2012174061A1 (en) 2011-06-14 2012-06-13 Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm

Publications (1)

Publication Number Publication Date
TN2013000494A1 true TN2013000494A1 (en) 2015-03-30

Family

ID=54359612

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000494A TN2013000494A1 (en) 2011-12-09 2013-11-25 Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm

Country Status (1)

Country Link
TN (1) TN2013000494A1 (en)

Similar Documents

Publication Publication Date Title
PH12013502523A1 (en) Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
EA033689B9 (en) Inhibitors of kras g12c
EA201100030A1 (en) PYRAZOL COMPOUNDS 436
EA201071094A1 (en) TRIPLE-substituted 1,2,4-TRIAZOLES AS MODULATORS OF NICOTINE ACETYL-HOLINE RECEPTORS
PH12013501594A1 (en) Substituted indazole derivatives active as kinase inhibitors
TN2009000344A1 (en) Combinations of therapeutic agents for treating cancer
DK2324008T3 (en) Diarylpyrazole as protein kinase inhibitors
MX2010006799A (en) Benzofuropyrimidinones as protein kinase inhibitors.
EA201100971A1 (en) DERIVATIVES OF PYRIMIDININDOL FOR THE TREATMENT OF MALIGNANT NORMALIZATION
NZ716487A (en) Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
JO2885B1 (en) Protein kinase inhibitors
MX336051B (en) Diarylacetylene hydrazide containing tyrosine kinase inhibitors.
EA201692167A1 (en) MODULATORS OF TOLL-SECONDARY RECEPTORS
MX2013001361A (en) 4-(1h-indol-3-yl) -pyrimidines as alk inhibitors.
SG194756A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
EA201071288A1 (en) TRIPLE PYRAZOLES AS MODULATORS OF ACETYLCHOLINE RECEPTORS
NZ606246A (en) Anticancer derivatives, preparation thereof and therapeutic use thereof
UA104489C2 (en) Compounds for the treatment of dyslipidemia and related diseases
MX2016004936A (en) Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquin oline derivatives, pharmaceutical compositions containing them, and their use in therapy.
MX2014006004A (en) N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy.
IN2015DN00528A (en)
MY172729A (en) Pharmaceutical formulations
EA201390984A1 (en) HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA
MX2014007878A (en) FORMULATIONS OF (+) - 2 - [1 - (3 - ETOXI - 4 - METOXI - PHENYL) - 2 - METANSULFONIL - ETIL] - 4 - AMINOISOINDOLIN OIL - 1, 3 - DIONA.
MY165902A (en) Substituted pyridine derivatives as fabi inhibitors